COVID-19 trials registries data warehouse

http://www.chictr.org.cn/showproj.aspx?proj=49297

Qin Ning

31531955@qq.com

2020-02-11

Recruiting

RCT

Randomized

Parallel

Not reported

single-center

Treatment

1. Aged >=18 to 70 years, 2. Diagnosed 2019-nCoV infected patients by viral nucleic acid,or although the test was negative and even not be detected, the reseachers judged it to be a novel coronavirus pneumonia, 3. Understand and agree to participate in this study and sign informed consent, 4. According to the guideline of clinical classification of novel coronavirus pneumonia (2019-nCoV) diagnosis and treatment plan (trial version fifth), the general patients were included in the selection criteria: fever, respiratory tract symptoms, imaging findings of pneumonia, Severe patients were selected according to the following criteria: 1) respiratory distress, RR >= 30 times / minute, 2) resting state, mean oxygen saturation less than 93%, 3) artery. PaO2 / FiO2 <= 300MMHG (1mmhg = 0.133kpa).

1. Pregnant or lactating women, or pregnant, 2. Those who are allergic to the drug ingredients of this program, 3. Severe cardiovascular diseases, such as severe center of gravity dysfunction, second or third degree atrioventricular block, etc., 4. Severe hepatic insufficiency: defined as the upper limit of ALT > 2 times normal value or AST > 2 times normal value, 5. Severe renal insufficiency: defined as creatinine > 1.5 times the upper limit of normal value, 6. Have asthma, COPD serious respiratory disease, 7. Serious blood diseases, such as coagulation disorders, systemic bleeding, platelet diseases, etc, 8. Serious endocrine system diseases, such as type II diabetes, 9. Patients with malignant tumor, 10. Patients taking antiedematous drugs for a long time, 11. Major operation history, 12. Other clinical researchers.

5

Tongji Hospital;Tongji Medical College; Huazhong University of Science and Technology

18

70

China

Moderate/severe disease at enrollment

4: Moderate/severe disease at enrollment

90

Chest imaging (CT);

| Declared number of arm (5.0) differs from found arms (6.0)

Phase 4

[{"arm_notes": "", "treatment_id": 329, "treatment_name": "Corticosteroid", "treatment_type": "Corticosteroids", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 1212, "treatment_name": "Sodium aescinate", "treatment_type": "Cardiovascular agents", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 1212, "treatment_name": "Sodium aescinate", "treatment_type": "Cardiovascular agents", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}]